Blue Circle Health exists to improve the health of people living with type 1 diabetes (T1D).
Our plan to do so involves:
1) building on investment from The Leona M. and Harry B. Helmsley Charitable Trust to design and deliver care for thousands; 2) collaborating with others in the T1D community to expand our reach; 3) sharing lessons learned inform better T1D care everywhere; and 4) offering the Blue Circle Health care program to every payor and policy maker interested in better outcomes at lower cost across the U.S.
We are proud of the progress we’ve made in Phase 1, having cared for more than 1,400 people across 20 states plus the District of Columbia. We have demonstrated statistically significant and clinically meaningful reductions in A1c and diabetes distress and are in the process of publishing the results.
Now, we are entering Phase 2. With that, we are inviting others in the T1D community to invest in our program to improve the lives of thousands while working toward better care for everyone living with T1D. This includes partnerships with the T1D drug and device manufacturers that create innovations that improve lives.
We recognize that partnering with T1D drug and device manufacturers creates opportunities for conflicts of interest. With that, we’d like to be crystal clear about how we will partner with T1D drug and device manufacturers.
Our Commitments to Independence
Blue Circle Health’s clinical decisions, research priorities, safety-related communications, and publication content are, and will only ever be, determined by our clinical and research teams, independent of fundraising considerations and industry partnerships.
We will never:
- Endorse or prescribe a specific product as a result of a donation.
- Make a commission or generate revenue from recommending products.
- Share or sell personal, prescription, or usage information with or to an industry partner.
- Refrain from expressing our views on harmful practices or expressing support for policy changes that are in the best interest of people living with T1D because of industry partner donations.
- Grant any industry partner advance access to, review of, or approval rights over our research findings, publications, or safety-related communications prior to public release.
- Provide data, analysis, or community insights to industry partners that are not also publicly available through our published research and reports.
- Refrain from communicating safety-related information because of industry partner donations.
Research and Publication Independence
Blue Circle Health is committed to publishing real-world outcomes data, clinical findings, and program evaluations in peer-reviewed medical journals and public reports. Our participant population, which includes a significant proportion of individuals from underserved communities, offers insights that are underrepresented in existing T1D literature. We have both an opportunity and an obligation to contribute these perspectives to the broader evidence base.
- Blue Circle Health will maintain full editorial independence over all of our research and publications.
- No industry partner, funder, or external organization will have the right to review, approve, delay, or influence the content or timing of our publications.
- Industry partners will receive the same access to our published findings as the general public.
Safety Communications
In situations where Blue Circle Health communicates safety-related information to our participants, we will do so in a manner that is appropriate in our clinical judgment and in consideration of the medical interests of our members. We will not consider in any respect whether the manufacturer of a product at issue is or is not an industry partner.
Our Industry Partnerships
- Industry partner donations of money, drugs, devices, or supplies will go to the Blue Circle Foundation, a 501(c)(3) we created to support our mission.
- Every donation we receive will go directly toward improving the health of the people living with T1D that we serve.
- The identity of industry donors will be publicly disclosed.
Blue Circle Health’s Commitment to Industry Partners
- We will ensure that our clinical team members are properly trained in how to use all T1D products, including those manufactured by our industry partners. We do this routinely as part of educating our providers and we will never limit our education to only include industry partner products.
- When we host or participate in community events designed to educate the public on available T1D technologies (e.g., “Technology Day”), we will include whatever innovations our clinical team deems appropriate, regardless of whether or not those innovations are manufactured by industry partners. Any donations will be disclosed as part of these events.
- We will publicly acknowledge the support that we receive from industry partners.
- We will share the impact of industry partner donations through participant-approved testimonials and through our publicly available research and outcomes reports. Industry partners will receive the same published findings as the general public, and no proprietary or advanced data access will be provided.
- Industry partners may use co-branding (including the Blue Circle Health logo) in materials that reference their support of our mission, in accordance with our brand guidelines.
- Industry partners will be invited to attend Blue Circle Health’s public community events and conferences, where our findings and community perspectives will be shared openly.
